Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 9/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585026 | 0.96 | QDPR (0.53) | QDPRHTR2CSLC18A3SIGMAR1HTR6 | |
| SCHEMBL1363874 | 0.91 | HTR3A (0.53) | QDPRHTR6DRD3HTR3AHTR2A | |
| SCHEMBL9746450 | 0.82 | EPHX2 (0.49) | — | |
| SCHEMBL31290248 | 0.82 | ALDH1A1 (0.41) | QDPR | |
| SCHEMBL5456534 | 0.81 | HRH3 (0.62) | QDPRHTR6DRD3HRH3 | |
| SCHEMBL5456547 | 0.81 | HRH3 (0.59) | QDPRSLC18A3HTR6DRD3HRH3 | |
| SCHEMBL10879536 | 0.79 | EPHX2 (0.49) | — | |
| SCHEMBL23917459 | 0.78 | KDM4C (0.39) | HRH3 | |
| SCHEMBL5584643 | 0.77 | QDPR (0.45) | QDPRHTR2CSLC18A3SIGMAR1HTR6 | |
| SCHEMBL5584630 | 0.77 | QDPR (0.45) | QDPRHTR2CSLC18A3SIGMAR1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | QDPR 214/4885HTR2C 9/4885SLC18A3 162/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | QDPR 214/4885HTR2C 9/4885SLC18A3 162/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | QDPR 658/4885HTR2C 1120/4885SLC18A3 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.